BioSig Technologies Inc (NASDAQ:BSGM) was the target of a significant growth in short interest in November. As of November 29th, there was short interest totalling 1,940,000 shares, a growth of 10.9% from the November 14th total of 1,750,000 shares. Approximately 12.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 68,300 shares, the days-to-cover ratio is presently 28.4 days.
Separately, ValuEngine upgraded BioSig Technologies from a “sell” rating to a “hold” rating in a research report on Monday, November 25th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in shares of BioSig Technologies by 1,264.7% in the 2nd quarter. BlackRock Inc. now owns 810,478 shares of the company’s stock valued at $7,610,000 after purchasing an additional 751,089 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of BioSig Technologies by 134.1% in the 2nd quarter. Vanguard Group Inc. now owns 585,771 shares of the company’s stock valued at $5,501,000 after purchasing an additional 335,573 shares during the last quarter. State Street Corp lifted its stake in shares of BioSig Technologies by 17.5% in the 3rd quarter. State Street Corp now owns 264,004 shares of the company’s stock valued at $2,178,000 after purchasing an additional 39,403 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of BioSig Technologies in the 3rd quarter valued at $845,000. Finally, Northern Trust Corp lifted its stake in shares of BioSig Technologies by 410.1% in the 2nd quarter. Northern Trust Corp now owns 66,789 shares of the company’s stock valued at $628,000 after purchasing an additional 53,696 shares during the last quarter. 14.69% of the stock is currently owned by institutional investors.
About BioSig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.